Boykо, A.,
Fernández, O.,
Alifirova, V.,
Babicheva, N.,
Bakhtiyarova, K.,
Volkov, A.,
Glavinskaya, N.,
Goncharova, Z.,
Greshnova, I.,
Smagina, I.,
Lashch, N.,
Inzhinova, A. (2021) to start with the second line of
disease-modifying therapy (DMT), a lower percentage would choose dimethyl
Роль мутаций в гене NF1 в спорадическом канцерогенезе. Prospects for gene
therapy of these
diseases are considered. © 2021 Uspehi Molekularnoj Onkologii. All